Publications

Selected Publications by CPRE Investigators and Researchers

Sophia M. Castillo, Noelle Cataldo, Cody J. Wenthur. Assessing logistical and ethical barriers for psychedelic-assisted therapy implementation: A cross-sectional pharmacist survey. Psychedelics 3 (2026) doi: 10.1016/j.psyche.2026.100017
A.M. Ortiz Bernal, C.L. Raison, A.M. Vargas, Prieto, A.K. Davis. Fabricated ancestrality: The Sonoran Desert toad, psychedelic globalization, and the ecological politics of 5-MeO-DMT. Psychedelics 3 (2026) doi: 10.1016/j.psyche.2026.100012
Haber I, Bok I, Kutler B, Nornberg M, Banks MI, Hai A. Acute DOI exposure drives cortical hyperexcitability and functional network remodeling. bioRxiv [Preprint]. 2026 May 21:2026.05.18.726129. doi: 10.64898/2026.05.18.726129. PMID: 42239078
Sutherland MH, Nicholas CR, Lennertz RC, Wenthur CJ, Krause BM, Sauder CJ, Riedner BA, Smith RF, Hutson PR, Raison CL, Banks MI. Electrophysiological effects of psilocybin co-administered with midazolam. Transl Psychiatry. 2026 Feb 14;16(1):160. doi: 10.1038/s41398-026-03894-x. PMID: 41688423.
Dourron HM, Copes H, Grossman DH, Bradley M, Nicholas CR, Turner JA, Allen-Clark G, Gossage M, Hendricks PS. How do psychedelics impact people with a history of non-affective psychosis? A qualitative study. Front Psychiatry. 2025 Dec 9;16:1716545. doi: 10.3389/fpsyt.2025.1716545. eCollection 2025.
Frautschi PC, Singh AP, Stowe NA, Grady SM, Zahid Z, Banks MI, Yu JJ. Effects of Psilocybin on Mouse Brain Microstructure. AJNR Am J Neuroradiol. 2025 Jun 3;46(6):1216-1222. doi: 10.3174/ajnr.A8634. PMID: 39880687
Enriquez UM, González Velázquez NM, Hossain MM, Kyzer JL, Guzei IA, Wenthur CJ. Generation of enantiospecific monoclonal antibodies against (2R,6R)-hydroxynorketamine. Bioorg Med Chem. 2026 Apr;135:118573. doi: 10.1016/j.bmc.2026.118573. Epub 2026 Jan 17. PMID: 41570529
Ortiz Bernal AM, Raison CL, Lancelotta RL, Timmermann C, Sepeda ND, Davis AK. Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence, Predictors, and Emotional Valence. J Psychoactive Drugs. 2025 Oct 23:1-11. doi: 10.1080/02791072.2025.2577305. Online ahead of print .PMID: 41129673
Palitsky R, Maples-Keller JL, Peacock C, Dunlop BW, Mletzko T, Grant GH, Raison CL, Chao S, Shub I, Mendelbaum-Kweller M, Smolyar L, Kaplan DM, Rothbaum BO, Zarrabi AJ. A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. Psychotherapy (Chic). 2025 Sep;62(3):348-362. doi: 10.1037/pst0000551. Epub 2025 Jan 13.PMID: 39804360
Razidlo J, Cataldo N, Wenthur CJ. Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice. ACS Pharmacol Transl Sci. 2025 Sep 11;8(10):3631-3640. doi: 10.1021/acsptsci.5c00462. eCollection 2025 Oct 10.PMID: 41244305.
Lee SJ, Epland C, Kaitz N, Shiyanbola O, Wenthur CJ. Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings. Sci Rep. 2025 Jul 21;15(1):26500. doi: 10.1038/s41598-025-12613-3. PMID: 40691491.
Bahceci D, Siefried K, Steele M, Harrod M, Bell G, Barratt MJ, Nicholas CR, Rodgers A, Hendricks PS, Stauffer CS, Liknaitzky P, Brett J. Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey. Drug Alcohol Depend. 2025 Jul 1;272:112699. doi: 10.1016/j.drugalcdep.2025.112699. Epub 2025 May 8. PMID: 40382852
Hutson PR.Psilocybin Dispensaries and Advertising-Buyer Beware. JAMA Netw Open. 2025 Apr 1;8(4):e252858. doi: 10.1001/jamanetworkopen.2025.2858. PMID: 40168028 Free article. No abstract available.
Brouwer A, Brown JK, Erowid E, Erowid F, Thyssen S, Raison CL, Carhart-Harris RL. A qualitative analysis of the psychedelic mushroom come-up and come-down. Npj Ment Health Res. 2025 Feb 7;4(1):6. doi: 10.1038/s44184-024-00095-6. PMID: 39915687 Free PMC article.
Palitsky R, Canby NK, Van Dam NT, Levin-Aspenson HF, Kaplan DM, Maples-Keller J, Raison CL, Grant GH, Dunlop BW, Britton WB. Leveraging meditation research for the study of psychedelic-related adverse effects. Int Rev Psychiatry. 2024 Dec;36(8):841-855. doi: 10.1080/09540261.2024.2420745. Epub 2024 Nov 13.PMID: 39980218 Review.
O’Donnell KC, Okano L, Alpert M, Nicholas CR, Thomas C, Poulter B, Mithoefer A, Mithoefer M, Ot’alora G M. The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD. Front Psychol. 2024 Nov 4;15:1427531. doi: 10.3389/fpsyg.2024.1427531. PMID: 39559692. eCollection 2024.
Zahid Z, Sultan ZW, Krause BM, Wenthur CJ, Pearce RA, Banks MI. Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity. Psychedelic Med (New Rochelle). 2024 Sep;2(3):166-177. doi: 10.1089/psymed.2023.0061. Epub 2024 Sep 4. PMID: 39669671.
Brouwer A, Carhart-Harris RL, Raison CL. Psychotomimetic compensation versus sensitization. Pharmacol Res Perspect. 2024 Aug;12(4):e1217. doi: 10.1002/prp2.1217. PMID: 38923845 Free PMC article. Review.
Witowski CG, Hess MR, Jones NT, Pellitteri Hahn MC, Razidlo J, Bhavsar R, Beer C, Gonzalez-Velazquez N, Scarlett CO, Wenthur CJ, von Salm JL. Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT). Eur J Pharm Sci. 2024 Aug 1;199:106803. doi: 10.1016/j.ejps.2024.106803. PMID: 38264637. Epub 2024 May 23.
Palitsky R, Kaplan DM, Perna J, Bosshardt Z, Maples-Keller JL, Levin-Aspenson HF, Zarrabi AJ, Peacock C, Mletzko T, Rothbaum BO, Raison CL, Grant GH, Dunlop BW. A framework for assessment of adverse events occurring in psychedelic-assisted therapies. J Psychopharmacol. 2024 Aug;38(8):690-700. doi: 10.1177/02698811241265756. Epub 2024 Jul 31.PMID: 39082259 Free article.
Siegel JS, Subramanian S, Perry D, Kay BP, Gordon EM, Laumann TO, Reneau TR, Metcalf NV, Chacko RV, Gratton C, Horan C, Krimmel SR, Shimony JS, Schweiger JA, Wong DF, Bender DA, Scheidter KM, Whiting FI, Padawer-Curry JA, Shinohara RT, Chen Y, Moser J, Yacoub E, Nelson SM, Vizioli L, Fair DA, Lenze EJ, Carhart-Harris R, Raison CL, Raichle ME, Snyder AZ, Nicol GE, Dosenbach NUF. Psilocybin desynchronizes the human brain. Nature. 2024 Aug;632(8023):131-138. doi: 10.1038/s41586-024-07624-5. Epub 2024 Jul 17.PMID: 39020167 Free PMC article.
Peacock C, Mascaro JS, Brauer E, Zarrabi AJ, Dunlop BW, Maples-Keller JL, Grant GH, Raison CL, Rab F, Palitsky R. Spiritual health practitioners’ contributions to psychedelic assisted therapy: A qualitative analysis. PLoS One. 2024 Jan 2;19(1):e0296071. doi: 10.1371/journal.pone.0296071. eCollection 2024.PMID: 38166057 Free PMC article.
Jones NT, Wagner L, Hahn MCP, Scarlett CO, Wenthur CJ. In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin. Front Psychiatry. 2024 Jan 8;14:1303365. doi: 10.3389/fpsyt.2023.1303365. PMID: 38264637. eCollection 2023.
Miller M, Meyers M, Martin A, Napolitano S, Dorsen C, Penn A, Rosa WE. A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care. J Hosp Palliat Nurs. 2024 Dec 19. doi: 10.1097/NJH.0000000000001096. Epub ahead of print. PMID: 39699865.
O’Donnell KC, Okano L, Alpert M, Nicholas CR, Thomas C, Poulter B, Mithoefer A, Mithoefer M, Ot’alora G M. The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD. Front Psychol. 2024 Nov 4;15:1427531. https://pubmed.ncbi.nlm.nih.gov/39559692/
Nicholas CR, Banks MI, Lennertz RC, Wenthur CJ, Krause BM, Riedner BA, Smith RF, Hutson PR, Sauder CJ, Dunne JD, Roseman L, Raison CL. (2024). Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience. Transl Psychiatry. Sep 12;14(1):372. https://pmc.ncbi.nlm.nih.gov/articles/PMC11393325/
Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., Barrett, F. S., Bogenschutz, M. P., Carhart-Harris, R., Ching, T. H. W., Cosimano, M. P., Danforth, A., Davis, A. K., Garcia-Romeu, A., Griffiths, R., Grob, C. S., Gründer, G., Gukasyan, N., Heinzerling, K. G., Hendricks, P. S., Holze, F., Horton, D. M., Johnson, M. W., Kelmendi, B., Knatz Peck, S., Koslowski, M., Liechti, M. E., Mertens, L. J., Moreno, F. A., Nayak, S. M., Nicholas, C. R., Preller, K. H., Rieser, N. M., Ross, S., Sergi, K., Sloshower, J., Smigielski, L., Stenbæk, D. S., Vollenweider, F. X., Weiss, B., Wolff, M., & Yaden, M. E. A field-wide review and analysis of study materials used in psilocybin research and their possible effects on expectancy. Psychedelic Medicine. 2024 1(1), 12–25. https://doi.org/10.1089/psymed.2024.0019
Wehrman JJ, Casey C, Tanabe S, Mohanta S, Filbey W, Weber L, Banks MI, Pearce RA, Saalmann Y, Sanders RD. Subanaesthetic doses of ketamine reduce but do not eliminate predictive coding responses: implications for mechanisms of sensory disconnection. Br J Anaesth. 2023 Oct;131(4):705-714. doi: 10.1016/j.bja.2023.06.044. Epub 2023 Aug 3. PMID: 37541951.
Nicholas, C.R., Horton, D.M., Malicki, J., Baltes, A., Hutson, P.R., Brown, R.T. Psilocybin for opioid use disorder in two adults stabilized on buprenorphine: A technical report on study modifications and preliminary findings. Psychedelic Medicine. 2023 1(4), 253-261. https://www.liebertpub.com/doi/10.1089/psymed.2023.0012
Mitchell, J.M., Ot’alora G., M., van der Kolk, B. et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29, 2473–2480 (2023). https://doi.org/10.1038/s41591-023-02565-4
Palitsky R, Kaplan DM, Peacock C, Zarrabi AJ, Maples-Keller JL, Grant GH, Dunlop BW, Raison CL. Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies. JAMA Psychiatry. 2023 Jul 1;80(7):743-749. doi: 10.1001/jamapsychiatry.2023.1554. PMID: 37256584
Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843–853. doi:10.1001/jama.2023.14530
Miller, M., Rosa, W., Rinaldi, A., Addicott, K., Spence, D., Beaussant, Y. Applying key lessons from the palliative care movement to inform psychedelic-assisted therapy. Psychedelic Medicine. Epub 2023 May 15. doi: 10.1089/psymed.2022.0009
Brett J, Knock E, Korthuis PT, Liknaitzky P, Murnane KS, Nicholas CR, Patterson JC II and Stauffer CS. Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Front. Psychiatry. 2023 14:1123424. doi: 10.3389/fpsyt.2023.1123424
Ortiz Bernal AM, Raison CL, Lancelotta RL, Davis AK. Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. Front Psychiatry. 2022 Nov 29;13:1049643. doi: 10.3389/fpsyt.2022.1049643. eCollection 2022. PMID: 36523876 Free PMC article.
Lehto RH, Miller M, Sender J. The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research. J Holist Nurs. 2022 Sep;40(3):265-280. doi: 10.1177/08980101211039086. Epub 2021 Sep 6.PMID: 34482761
Bradberry MM, Gukasyan N, Raison CL.Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies. JAMA Psychiatry. 2022 Jun 1;79(6):525-527. doi: 10.1001/jamapsychiatry.2022.0665. PMID: 35476015 Free PMC article. No abstract available.
Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, Emerson A, Brown RT, Doblin R. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022 Apr 1;233:109356. doi: 10.1016/j.drugalcdep.2022.109356. Epub 2022 Feb 11. PMID: 35286849.
Rosa, W., Sager, Z., Miller, M. R., Bjerre, C., Bernstein, I… Beaussant, Y. (2022). Top ten tips palliative care clinicians should know about psychedelic-assisted therapy. Journal of Palliative Medicine, 25(8), 1273-1281. doi: 10.1089/jpm.2022.0036
Lehto, R. H., Miller, M., Sender, J. Emerging trends in managing cancer-related distress: The role of psilocybin-assisted psychotherapy. Journal of Holistic Nursing. 2022 40(3), 265-280. doi: 10.1177/08980101211039086
Raison CL, Jain R, Penn AD, Cole SP, Jain S. Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. Front Psychiatry. 2022 Mar 15;13:831092. doi: 10.3389/fpsyt.2022.831092. PMID: 35370864; PMCID: PMC8965278.
Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot’alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 Jun;27(6):1025-1033. doi: 10.1038/s41591-021-01336-3. Epub 2021 May 10. PMID: 33972795; PMCID: PMC8205851.
Matthew I. Banks, Zarmeen Zahid, Nathan T. Jones, Ziyad W. Sultan, and Cody J. Wenthur. Catalysts for change: the cellular neurobiology of psychedelics. Molecular Biology of the Cell. 2021 32:12, 1135-1144.
L Richert, E Dyck. Psychedelic crossings: American mental health and LSD in the 1970s. Medical Humanities. 2020 Sep;46(3):184-191. doi: 10.1136/medhum-2018-011593. Epub 2019 Jun 23.
Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM; the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020 May 1;177(5):391-410. doi: 10.1176/appi.ajp.2019.19010035. Epub 2020 Feb 26. PMID: 32098487.
Dahmane E, Hutson PR, Gobburu JVS. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin. Clin Pharmacol Drug Dev. 2020 Apr 6. doi: 10.1002/cpdd.796. PMID: 32250059.
Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res. 2020 Feb;284:112749. doi: 10.1016/j.psychres.2020.112749. Epub 2020 Jan 2. PMID: 31931272.
Goldberg SB, Shechet B, Nicholas CR, Ng CW, Deole G, Chen Z, Raison CL., Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychol Med. 2020 Dec; 50(16):2655-2666. doi: 10.1017/S003329172000389X. Epub 2020 Nov 4.
N Schmitz, L Richert. Pharmacists and the future of cannabis medicine. Journal of the American Pharmacists Association. Jan-Feb 2020;60(1):207-211. doi: 10.1016/j.japh.2019.11.007. Epub 2019 Dec 20.
L Richert, M DeCloedt. Supple bodies, healthy minds: yoga, psychedelics and American mental health. Medical Humanities. 2018; 44 (3), 193-200.
Nicholas CR, Henriquez KM, Gassman MC, Cooper KM, Muller D, Hetzel S, Brown RT, Cozzi NV, Thomas C, Hutson PR. High dose psilocybin is associated with positive subjective effects in healthy volunteers. J Psychopharmacol. 2018 Jul;32(7):770-778. doi: 10.1177/0269881118780713. Epub 2018 Jun 27. PMID: 29945469.
Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017 Dec;56(12):1543-1554. doi: 10.1007/s40262-017-0540-6. PMID: 28353056.